Skip to content
naulon

No retraction, correction or concern found when last checked on Oct 26, 2026.

Gut microbiota and fecal short chain fatty acids differ with adiposity and country of origin: the METS-microbiome study

Gertrude Ecklu-Mensah, Candice Choo-Kang, Maria Gjerstad Maseng and 16 more

Nature Communications · 2023 · CC BY

doi:10.21203/rs.3.rs-2791107/v1

Abstract

The relationship between microbiota, short chain fatty acids (SCFAs), and obesity remains enigmatic. We employ amplicon sequencing and targeted metabolomics in a large ( n = 1904) African origin cohort from Ghana, South Africa, Jamaica, Seychelles, and the US. Microbiota diversity and fecal SCFAs are greatest in Ghanaians, and lowest in Americans, representing each end of the urbanization spectrum. Obesity is significantly associated with a reduction in SCFA concentration, microbial diversity, and SCFA synthesizing bacteria, with country of origin being the strongest explanatory factor. Diabetes, glucose state, hypertension, obesity, and sex can be accurately predicted from the global microbiota, but when analyzed at the level of country, predictive accuracy is only universally maintained for sex. Diabetes, glucose, and hypertension are only predictive in certain low-income countries. Our findings suggest that adiposity-related microbiota differences differ between low-to-middle-income compared to high-income countries. Further investigation is needed to determine the factors driving this association.

Full text

From PubMed Central, U.S. National Library of Medicine, as current on Oct 26, 2026. Paragraph numbers are ours, so an answer can point at one.

Introduction

Obesity, which affects more than 600 million adults worldwide (“), over a third of Americans, and accounts for over 60% of deaths related to high body mass index (BMI), remains an ongoing global health epidemic that continues to worsen at an alarming rate. A major driver of obesity is the adoption of a western lifestyle, which is characterized by excessive consumption of ultra-processed foods. Obesity is a major risk factor for type 2 diabetes, and according to the most recent National Diabetes Statistics Report almost 13% of the adult US population now have diabetes. Not only do 49.6% of adult African Americans present with obesity but over 17% of them now have diabetes, and are 1.5 times as likely to present with type 2 diabetes compared to whites (“). Populations of African origin outside of the US are experiencing similar fates, as the prevalence of obesity among adults living in Sub-Saharan Africa is greater than 13%, and higher than the global obesity prevalence for adults. This has been accompanied by dramatic increases in the prevalence of non-communicable diseases such as type two diabetes and hypertension among people of African origin. Therefore, disrupting the rapidly expanding obesity epidemic, particularly among African origin populations is critical to controlling the cardiometabolic disorder epidemic. However, successfully managing and treating obesity and its comorbidities, and specifically maintaining weight loss long-term, is particularly challenging due to an incomplete understanding of the heterogeneous and complex etiopathology, as well as additional challenges facing populations experiencing rapid urbanization (Nordmo, Danielsen, and;; ). The epidemiologic transition is a model able to capture these shifts in dietary and rural to urban movements and is characterized by diets that are high in ultra-processed foods with a significant loss in fiber, as evidenced in the US, where less than 50% of the population meet dietary fiber recommendations.

Gut microbial ecology and metabolism play pivotal roles in the onset and progression of obesity and its related metabolic disorders. Obese and lean individuals have reported differences in the composition and functional potential of the gut microbiome, with an overall reduction in species diversity in the obese gut (;;;;; Le ), additionally, fecal microbiota transfer from obese donors to mouse models can recapitulate the obese phenotype. Further, fecal microbiota transplant from healthy donors into patients with obese and metabolic syndrome has been shown to improve markers of metabolic health in the recipients. While these studies suggest that modification of microbial ecology may offer new options for the treatment and prevention of obesity, the mechanism that drives the microbiota-obesity relationship is not fully understood. The microbiota may facilitate greater energy exploitation from food, and storage capacity by the host, influencing adipose tissue composition and fat mass gain, as well as providing chronic low-grade inflammation and insulin resistance.

Among the numerous microbial metabolites modulating obesity, there is an ever-growing interest in the role of short-chain fatty acids (SCFAs), which includes butyrate, acetate, and propionate as potential biomarkers for metabolic health as well as therapeutic targets. SCFAs derive primarily from microbial fermentation of non-digestible dietary fiber in the colon. They have many effects on host metabolism including serving as an energy source for host colonocytes, used as precursors for the biosynthesis of cholesterol, lipids, proteins and regulating gut barrier activities. Human and animal studies demonstrate a protective role of SCFAs in obesity and metabolic disease. In experimental animal models, SCFA supplementation reduces body weight, improves insulin sensitivity, and reduces obesity-associated inflammation. In humans, increased gut production of butyrate correlates with improved insulin response after an oral glucose-tolerance test. Although increased SCFA levels are generally observed as positive for health, other studies have suggested that overproduction may promote obesity, possibly resulting from greater energy accumulation. Indeed, a previous study observed greater fecal SCFA concentrations to be linked with obesity, increased gut permeability, metabolic dysregulation, and hypertension in a human cohort.

The conflicting obesity role of SCFAs identified by existing studies may result from the variation in the gut microbiota, which is shaped by lifestyle and diet. Adequately powered studies in well-characterized populations may permit more rigorous assessments of individual differences. Prior comparative epidemiological studies have broadly focused on either contrasting the gut microbiota of extremely different populations, such as the traditional hunter-gatherers and urban-westernized countries, or ethnically homogenous populations. Demographic factors represent one of the largest contributors to the individualized nature of the gut microbiome. The five diverse, well-defined cohorts from the Modeling the Epidemiologic Transition Study (METS) offers a unique opportunity to examine the issues since they are more representative of most of the world’s population. METS has longitudinally followed an international cohort of approximately 2,500 African origin adults spanning the epidemiologic transition from Ghana, South Africa, Jamaica, Seychelles, and the US since 2010 to investigate differences in health outcomes utilizing the framework of the epidemiologic transition. Pioneering microbiome studies from the METS cohorts reveal that cardiometabolic risk factors including obesity is significantly associated with reduced microbial diversity, and the enrichment of specific taxa and predicted functional traits in a geographic-specific manner. While yielding valuable descriptions of the connections between the gut microbiota ecology and disease, particularly obesity, as well as pioneering the efforts of microbiome studies of populations of African origin on different stages of the ongoing nutritional epidemiologic transitions, these studies, however, have applied small sample size (N=100 to N=655), and also did not utilize all the countries in the METS cohort. Thus, uncertainties remain as to the precise interpretation of the microbiome-obesity associations, which hampers further progress towards diagnostic and clinical applications.

Our new study METS-Microbiome investigated associations between the gut microbiota composition and functional patterns, concentrations of fecal SCFAs and obesity in a large (N = 1,904) adult population cohort of African origin, comprised of Ghana, South Africa, Jamaica, Seychelles, and the US spanning the epidemiologic transition. The central hypothesis is that shifts towards the highest end of the epidemiologic transition spectrum is associated with alterations in microbiota diversity and community composition, reductions in levels of fecal SCFAs and obesity.

Obesity differs significantly across the epidemiological transition.

From 2018–2019, the METS-Microbiome study recruited 2,085 participants (~60% women) ages 35–55 years old from five different sites (Ghana, South Africa, Jamaica, Seychelles, and US). Of these participants, 1,249 have been followed on a yearly basis since 2010 under the parent METS study. Data from 1,867 participants with complete data sets were used in this analysis. Overall mean age was 42.5 ± 8.0 years (Table 1). Mean fasted blood glucose was 105.2 ± 39.4 mg/dL, mean systolic blood pressure was 123.4±18.1 mm Hg and mean diastolic blood pressure was 77.2 ± 13.1 (Table 1). When compared to the high-income countries (Jamaica, Seychelles, and US), both women and men from the lower- and middle-income countries (Ghana and South Africa) had significantly lower BMI, fasted blood glucose and blood pressure (systolic and diastolic). Mean BMI was lowest in the South African men (22.3 kg/m2 ± 4.1) and highest in US women (36.3 kg/m2 ± 8.8). When compared to the US, all sites had significantly lower prevalence of obesity (p<0.001 for all sites except for Seychelles: p=0.02). Prevalence of hypertension was lowest in Ghanaian men (33.1%) and highest in US men (72.7%). Prevalence of diabetes was lowest in South African women and men (3.5% for women and men) and highest for Seychellois men (22.8%). When compared to the US, prevalence of hypertension and diabetes was significantly lower in countries at the lower end of the spectrum of HDI (i.e., Ghana and South Africa) when compared to the US (p<0.001).

Microbial community composition and predicted metabolic potential differs significantly between countries and correlates with obesity.

Following the removal of samples that had fewer than 6,000 reads and features less than ten reads in the entire dataset, a total of 433,364,873 16S rRNA gene sequences were generated from the 1,873 fecal samples which were clustered into 13,254 ASVs. Country of origin describes most of the variation in microbial diversity and composition, with significant differences in both alpha and beta diversity. Although there were major variations in alpha diversity between countries and large degree of inter-individual variation within countries, Ghana showed significantly greater diversity for all the alpha diversity metrics (Observed ASVs, Shannon Diversity and Faith’s phylogenetic diversity) when compared to all other countries. The Seychelles and US had the lowest alpha diversity (Fig. 1). The stool microbiota alpha diversity of non-obese individuals was significantly greater when compared with that of obese individuals (Fig. 1). Beta diversity was also significantly different between countries (Fig. 1, Supplementary Tables 2 & 3; principal coordinate analysis, weighted UniFrac distance; F-statistic =58.67; p < 0.001; unweighted UniFrac distance; F= 39.87; p < 0.001) and obese group (weighted UniFrac distance; F-statistic =2.39; p = 0.031; unweighted UniFrac distance; F=6.06; p < 0.001).

Next, we compared fecal microbiota diversity between obese individuals with their non-obese counterparts within each country independently. Greater alpha diversity was detected in non-obese subjects in the Ghanaian (Observed ASVs, Faith PD; p<0.05) and South African cohorts (Observed ASVs; p<0.05) only (Supplementary Table 1). Similarly, significant differences in beta diversity between obese and non-obese microbiota were observed in Ghana (Unweighted UniFrac; p<0.05), South Africa (Unweighted UniFrac; p<0.05) and US (Weighted UniFrac; p<0.05) data sets (Supplementary Tables 2 & 3). These results suggest that the beta diversity differences observed in the Ghanaian and South African participants may partly be due to the presence of more abundant fecal microbiota taxa in the fecal samples whereas among the US participants, the differences may be related to the abundance of rare taxa. Collectively, these observations suggest that country is a major driver of the variance in gut microbiota diversity and composition among participants with or without obesity with marked contributions from Ghana and South Africa and modest contribution from the US in the overall cohort.

We also examined whether country of origin or obesity relates to the presence of specific microbial genera frequently used to stratify humans into enterotypes. As expected, large differences in enterotype between the countries were observed. The Prevotella enterotype (P-type) was enriched on the African continent, with 81% and 62% in Ghanaians and South Africans respectively while Bacteroides enterotype (B-type) was dominant in the US (75%), Jamaican cohorts (68%), and comparable proportions of both enterotypes among individuals from Seychelles. Further, obese individuals displayed a greater abundance of B-type whereas a higher proportion of the P-type associated with the non-obese group (Supplementary Table 4). Consistent with this observation, the abundance of B-type correlated with higher BMI (p=0.004) than P-type. Significantly greater diversity and increased levels of total SCFA were observed in participants in the P-type (Supplementary Table 4). The relative abundance of shared and unique features between the different countries illustrated by the Venn diagram showed that Ghana carries the largest proportion of unique taxa than the other countries, and US the lowest (Fig. 1).

Microbial taxa differ significantly between countries and between lean and obese individuals.

In comparison with the US, South African fecal microbiota had a significantly greater proportion of Clostridium, Olsenella, Bacilli and Mogibacterium; Jamaican samples had a significantly greater proportion of Bacilli, Bacteroides, Clostridia, Dialister, Enterobacteriaceae, and Oscillospiraceae; Seychelles samples had a significantly greater proportion of Clostridium, Olsenella and Haemophilus; and Ghanaian samples had a significantly greater proportion of Clostridium, Prevotella, Weisella, Enterobacteriaceae and Butyricicoccaceae. The US samples had a significantly greater proportion of Aldercreutzia, Anaerostipes, Clostridium, Eggerthella, Eisenbergiella, Ruminococcaceae and Sellimonas compared to the 4 countries (Fig. 2 and Supplementary Fig. 1).

When adjusted for country, age, and sex (p < 0.05; false discovery rate (fdr)-corrected), 38 Amplicon Sequence Variants (ASVs) were significantly different between obese and non-obese groups. The obese group was characterized by an increased proportion of Allisonella, Dialister, Oribacterium, Mitsuokella, and Lachnospira, whereas non-obese microbiota had a significantly greater proportion of Alistipes, Bacteroides, Clostridium, Parabacteroides, Christensenella, Oscillospira, Ruminococcaceae (UBA1819), and Oscillospiraceae (UCG010) (Fig. 2).

Microbial taxonomic features predict obesity overall and within each country.

Using supervised Random Forest machine learning, the predictive capacity of the gut microbiota features in stratifying individuals to country of origin, sex, or with metabolic phenotypes were assessed. The predictive performance of the model was calculated by area under the receiver operating characteristic curve (AUC) analysis, which showed a high accuracy for country of origin (AUC = 0.97), and a comparatively lower level of predictive accuracy for obese state (AUC = 0.65) (Fig. 3). Sex was predicted with AUC = 0.75, the diabetes status with AUC = 0.63, hypertensive status with AUC = 0.65 and glucose status with AUC = 0.66. Random Forest analysis was also used to identify the top 30 microbial taxonomic features that differentiate between countries and obese states. Similar to the ANCOMBC results, Prevotella and Streptococcus were at a greater proportion in the microbiota of Ghanaian and non-obese individuals, whereas Mogibacterium was at a greater proportion in the South African cohort. A greater proportion of Megasphaera was associated with the Jamaican cohort, while a greater proportion of Ruminococcaceae was observed in the American microbiota. Weisella, which was identified as having a significantly greater proportion in the Ghanaian cohort using ANCOMBC, was observed to be a discriminatory feature for Seychelles microbiota using Random Forest (Supplementary Fig. 2).

Similarly, the predictive capacity of the gut microbiota features in stratifying individuals by obese state was assessed at each of the five study sites. The predictive performance of the model was calculated by AUC analysis, which showed a moderate accuracy for obese state for all sites, namely, Ghana (AUC = 0.57), South Africa (AUC = 0.52), Jamaica (AUC = 0.48), Seychelles (AUC = 0.43) and US (AUC = 0.52) (Supplementary Fig. 3).

Predicted genetic metabolic potential differs by country and obesity status.

The predicted potential microbial functional traits resulting from the compositional differences in microbial taxa between countries and obese state were assessed. PICRUSt2 predicted a total of 372 MetaCyc functional pathways. ANCOM-BC analysis adjusted for sex, age and BMI identified 67 pathways (p< 0.05; false discovery rate (fdr)-corrected), LFC>1.4) that accounted for discriminative features between the 4 different countries with the US (Supplementary Fig. 4). In comparison with US, MetaCyc pathways differentially increased in Ghana and Jamaica include methylgallate degradation, norspermidine biosynthesis (PWY-6562), gallate degradation I pathway, gallate degradation II pathway, histamine degradation (PWY-6185), and toluene degradation III (via p-cresol) (PWY-5181). South African samples had a greater proportion of L-glutamate degradation VIII (to propanoate) (PWY-5088), isopropanol biosynthesis (PWY-6876), creatinine degradation (PWY-4722), adenosyl cobalamin biosynthesis (anaerobic) (PWY-5507), respiration I (cytochrome c) (PWY-3781). MetaCyc pathways linked to norspermidine biosynthesis (PWy-6562), mycothiol biosynthesis (PWY1G-0), were at a greater proportion in the Seychelles samples, whereas reductive acetyl coenzyme A (CODH-PWY), and chorismate biosynthesis II (PWy-6165) were depleted in the US samples. ANCOM-BC analysis adjusted for site, sex and age identified 24 predicted pathways that differentiated between obese and non-obese individuals (Supplementary Fig. 4). Notably, the microbiota of non-obese individuals had a greater proportion of predicted pathways including the TCA cycle, amino acid metabolism (P162-PWY, PWY-5154, PWY-5345), ubiquinol biosynthesis-related pathways (PWY-5855, PWY-5856, PWY-5857, PWY-6708, UBISYN-PWY), cell structure biosynthesis and nucleic acid processing (PWY0 845, PYRIDOXSYN-PWY).

Next, KEGG orthology (KO) involved in pathways related to butanoate (butyrate) metabolism and LPS biosynthesis were investigated. Predicted genes involved in butyrate biosynthesis pathways showed that enoyl-CoA hydratase enzymes (K01825, K01782, K01692), lysine, glutarate /succinate enzymes (K07250, K00135, K00247), glutarate/Acetyl CoA enzymes (K00175, K00174, K00242, K00241 K01040, K01039) were differentially abundant in participants from Ghana, South Africa, Jamaica, and Seychelles in comparison to the US cohort. The relative abundance of succinic semialdehyde reductase (K18122) was significantly increased only in South Africa, Jamaica, and Seychelles population. Further, predicted genes proportionally abundant only in specific countries were observed. For instance, succinate semialdehyde dehydrogenase (K18119) was enriched only in the Ghanaian cohort, 4-hydroxybutyrate CoA-transferase (K18122) enriched among South African participants and lysine/glutarate/succinate enzyme (K14268) differentially abundant within the Seychelles population. The relative abundance of predicted genes encoded for enzymes such as maleate isomerase (K10799), 3-oxoacid CoA-transferase(K01027) and pyruvate/acetyl CoA (K00171, K00172, K00169) were greater in the US participants compared with participants from the 4 countries (Supplementary Fig. 5). The non-obese exhibited a significantly greater abundance of genes that catalyze the production of butyrate via the fermentation of pyruvate or branched amino-acids such as enoyl-CoA hydratase enzyme (K0182), Leucine/Acetyl CoA enzyme (K01640) and pyruvate/acetyl CoA enzyme (K00171, K00172, K00169, K1907) by contrast obese individuals were differentially enriched for succinyl-CoA:acetate CoA-transferase (K18118) (Supplementary Fig. 5). All analyses were adjusted for country, sex, BMI and age (fdr-corrected p < 0.05).

Several gut microbial predicted genes involved in LPS biosynthesis differentially enriched among the countries (p< 0.05; false discovery rate (fdr)-corrected) were identified. In particular, the relative abundance of specific LPS genes (K02560, K12973, K02849, K12979, K12975, K12974) were significantly enriched in Ghana, South Africa, Jamaica, and Seychelles when compared with US. Higher proportions of LPS genes including K12981, K12976 K09953, K03280 were significantly increased in Seychelles samples in comparison with US samples and also significantly increased in the US cohorts in comparison with participants from Ghana, South Africa, and Seychelles. US samples had a greater proportion of the following genes (K15669, K09778, K07264, K03273, K03271) in comparison with the other 4 countries (Supplementary Fig. 6). Non-obese individuals had a greater abundance of predicted genes encoding LPS biosynthesis (K02841, K02843, K03271, K03273, K19353, K02850) whereas only 1 LPS gene (K02841) differentially elevated in the non-obese group (Supplementary Fig. 6). All analyses were adjusted for country, sex, BMI and age (fdr-corrected p < 0.05).

Microbial community composition and taxonomy correlate with observed fecal SCFA concentrations.

All countries had significantly higher weight-adjusted fecal total SCFA levels when compared to the US participants (p<0.001), with Ghanaians having the highest weight-adjusted fecal total SCFA levels (Supplementary Table 5). When compared to their obese counterparts, non-obese participants had significantly higher weight-adjusted fecal total and individual SCFA levels (Supplementary Table 6). Total SCFA levels displayed weak, but significantly positive correlation with Shannon diversity (r = 0.0.074). A similar trend was observed in the different individual SCFAs, namely valerate (r = 0.19), butyrate (r = 0.12), propionate (r = 0.073) and acetate (r = 0.058) (Fig. 4). Observed ASVs were not significantly correlated with total SCFAs (p>0.05). Levels of acetate, butyrate and propionate exhibited strong significant correlations with total SCFA, whereas valerate levels significantly correlated negatively (r = −0.09) with total SCFAs. Next, we assessed if levels of total SCFAs could be predicted by a mixed model. Country explained 45.7% of the variation in SCFAs. No significant effect was explained either by obesity or Shannon diversity.

To explore the connection between SCFAs with gut microbiota, Spearman correlations between taxa that were proportionally significantly different between countries and concentrations of SCFAs were determined. Valerate negatively correlated with the proportion of Clostridium, Prevotella, Faecalibacterium, Roseburia and Streptococcus, which were all positively correlated with acetate, propionate, and butyrate. Similarly, the proportions of Christensenellaceae, Eubacterium, and UCG 002 (Ruminococcaceae) were significantly positively associated with valerate, and negatively correlated with acetate, propionate, and butyrate. In addition, only a single ASV annotated to Ruminococcus was observed to be positively associated with all 4 SCFAs (Fig. 5). Similarly, Spearman’s rank correlation coefficients were calculated between the differentially abundant ASVs identified between obese and non-obese group with concentrations of SCFAs. Broadly, the proportions of most ASVs were significantly positively associated with acetate in comparison with the other 3 SCFAs. Consistent with the correlations mentioned above, valerate negatively correlated with most ASVs that were found to be positively correlated with the three major SCFAs, acetate, propionate, and butyrate and vice versa. The relative proportions of ASVs belonging to Allisonella, Erysipelotrichaceae and Libanicoccus positively correlated with acetate, propionate, and butyrate, whereas significantly negative relationships were observed between Parabacteroides and Bacteroides abundances with the aforementioned SCFAs. Valerate showed significantly positive associations with Oscillospiralles and Ruminococcaceae abundances and significantly negative correlations with Lachnospira and Eggerthella abundances (Fig. 5).

Discussion

By leveraging a well characterized large population-based cohort of African origin residing in geographically distinct regions of Ghana, South Africa, Jamaica, Seychelles, and the US, we examined the relationships between gut microbiota, SCFAs and adiposity. Our data revealed profound variations in gut microbiota, which are reflected in the significant changes in community composition, structure, and predicted functional pathways as a function of population obesity and geography, despite their shared ancestral background. Our data further revealed an inverse relation between fecal SCFA concentrations, microbial diversity, and obesity; importantly, the utility of the microbiota in predicting whether an individual was lean or obese was inversely correlated with the income-level of the country of origin. Overall, our findings are important for understanding the complex relationships between the gut microbiota, population lifestyle and the development of obesity, which may set the stage for defining the mechanisms through which the microbiome may shape health outcomes in populations of African origin.

As reported previously our data showed that geographic origin can modulate the composition of the gut microbiota. Our findings were also consistent with our previous METS studies and other large scale continental cohort studies (De,;;;;;; ), that report a higher bacterial diversity and composition/microbial richness in traditionally non-western groups that distinguish them from urban-industrialized individuals whose diets are low in fiber and high in saturated fats. Although we observe enrichment in the relative abundance of several taxa associated with country of origin in our cohorts, we also detect a pattern where the gut microbiota of Ghanaian and South African cohort tends to share many features, while the gut microbiota of the Jamaican cohort shared many features with all 4 countries, possibly reflecting the ongoing epidemiological transitional nature of their communities represented by the overlap with western and traditionally non-western populations. Notably, traditionally non-western associated taxa including Prevotella, Butyrivibrio, Weisella and Romboutsia were enriched in participants from Ghana and South Africa, as suggested previously. Western-associated taxa such as Bacteroides and Parabacteroides were enriched in individuals from Jamaica and the US, while an ASV annotated as Olsenella was proportionally abundant in Seychelles microbiota. Bifidobacterium and Aldercreutzia were enriched in the US cohort. Clostridium sensu stricto 1 was over-represented in all 4 countries in comparison with the US. We also found greater enrichment of VANISH taxa including Butyricicoccus and Succinivibrio in the Ghanaian cohort, in line with individuals practicing traditional lifestyles. Prevotella is usually associated with plant-based diets rich in dietary fibers, while Bacteroides abundance broadly correlates with diets high in fat, animal protein, and sugars, which is in agreement with our enterotype analysis where a Prevotella-rich microbiota dominates the Ghanaian and South African gut, while a Bacteroides-rich microbiota dominated in the high-income countries. As Prevotella synthesizes SCFAs, its depletion may lead to the observed reduction in SCFA concentrations. Our results support a potential role for geography in reinforcing variations in the gut microbiota in our study cohort despite shared origin. Geography may reflect subtle shifts in lifestyle and/or environmental exposures including heterogeneity of dietary sources, exposure to medications, socioeconomic factors, medical history, and biogeographical patterns in microbial dispersion.

We also inferred the metabolic capacity of the gut microbiota associated with the different countries. Several metabolic pathways linked to carrier, cofactor and vitamin biosynthesis, biosynthesis/degradation of amines, amino acids, aromatic xenobiotics, and tricarboxylic acid (TCA) cycle were differentially enriched between the different countries compared with the US. These pathways are involved in biochemical reactions that regulate several processes including energy metabolism, inflammation, epigenetic processes, and oxidative stress. Participants from Ghana and Jamaica were enriched for gallate degradation, which can result in phenolic catechin metabolites which are thought to alleviate obesity-related pathologies. Additionally, glutamate metabolism, which can be fermented to butyrate and propionate, was enriched in South Africans and Ghanaians compared to the US. In the Seychelles, actinobacterial mycothiol biosynthesis was upregulated, which is involved in antioxidant activity and the removal of toxic compounds from cells. We further identified an increase in SCFA synthesis pathways, e.g. acetyl coenzyme A pathway, threonine biosynthesis, and leucine degradation in the microbiomes of all four countries compared to the US. Further studies are required to evaluate the potential causal relations of these gut microbial functions with health outcomes using shotgun metagenomic sequencing.

Preclinical mouse models provided early causal links between gut microbial ecology and obesity, suggesting the potential to predict obesity risk from the microbiome. However, prediction has proven difficult because results are conflicting. As we observed, the bulk of evidence from prior studies show that obesity is associated with a less diverse bacterial community. In addition, we identified several SCFA producing bacteria that were significantly depleted in obese individuals, which may influence host energy metabolism. For example, Oscillospira and Christensenella which were statistically associated with increases SCFA concentrations and reduced obesity have previously been associated with a lean phenotype, and produce SCFAs (; Gophna, Konikoff, and Nielsen 2017) including butyrate, which improves insulin sensitivity and reduces inflammation. We also detected several butyrate producing ASVs including Eubacterium, Alistipes, Clostridium and Odoribacter to be proportionally enriched in individuals who were non-obese. We observed that obese individuals presented a greater abundance of Lachnospira, which does produce SCFAs, a finding also consistent with our prior study in the same population, and others. However, other studies have observed the opposite.

SCFA supplementation has been documented to protect against a high-fat diet-induced obesity in mice as well as weight gain in humans. Conversely, other studies, mostly from western populations, have reported that elevated SCFA concentrations in stool can associate with obesity. For instance, a Colombian cohort showed associations between elevated fecal SCFA levels, central obesity, gut permeability, and hypertension. One potential explanation is that obese gut microbiota may lead to less efficient SCFA absorption, hence the increased SCFA excretion. However, as we found diets high in fiber correlate positively with weight loss and increased levels of fecal SCFAs (De ). One explanation may be in differences lifestyle factors, including medication, activity, and pollutant exposure, which could also impact intestinal absorption in western countries. We note that fecal SCFA concentrations are not a direct measure of intestinal SCFA production, but rather reflect a net result of the difference between production and absorption. Studies using stable isotopes to measure SCFA dynamics would improve interpretation of dichotomy.

While SCFAs associate with obese phenotype, another mechanism underpinning obesity is metabolic endotoxemia. An increase in Proteobacteria, which often accompanies a high fat/high sugar diet, is often associated with an increase in circulating lipopolysaccharide (LPS) and H2S, which provoke low-grade inflammation, increased intestinal permeability, and clock gene disruption in the liver, which associate with adiposity. We identified an increase in Dialister in obese individuals which has been associated with increased LPS production, obesity, sleep disruption and chronic inflammation. Collectively, our results demonstrate that obese individuals harbor a marked inflammatory state favoring the development of obesity, and this is in concordance with the associated metabolic endotoxemia pathway linking gut bacteria to obesity.

In obese individuals, as well as SCFA metabolism, we also detected marked depletion in pathways involved in cell structure, vitamin B6, NAD, and amino acid biosynthesis. This suggests that pathways important for growth and energy homeostasis are disrupted in individuals with obesity. We also noted an enrichment of the formaldehyde assimilation I (serine pathway) pathway. Endogenous formaldehyde produced at sufficient levels has carcinogenic properties and detrimental effects on genome stability. To counteract this reactive molecule, organisms have evolved a detoxification system that converts formaldehyde to formate, a less reactive molecule that can be used for nucleotide biosynthesis. Thus, we may infer that the pattern of increased formaldehyde assimilation pathway in our data might result from a defect or diminished capacity of formaldehyde detoxification system pathway, an assumption which requires further verification. A study reported increases in the abundance of formaldehyde assimilation pathway in a depressed group when compared with non-depressed controls. We are the first to show that the gut of obese participants is enriched in the formaldehyde assimilation pathway. Although we do not understand the mechanistic details, it is known that toxic formaldehyde is generated along with reactive oxygen species during inflammatory processes. Thus, an increased capacity for formaldehyde pathway may indicate a microbiome-induced increase in reactive oxygen species in the gut of obese individuals. Indeed, prior work has identified induction of oxygen stress by microbial perturbations as one of the mechanisms by which the microbiome can promote weight gain and insulin resistance. The specific alterations of the gut microbiota and the associated predicted functionality may constitute a potential avenue for the development of microbiome-based therapeutics to treat obesity and/or to promote and sustain weight loss.

Study strengths and limitations.

While our study has several strengths including a large sample size, diverse population along an epidemiological transition gradient with a comprehensive dataset that allowed the exclusion of the potential effects of origin as well as control of potential interpersonal covariates, and use of validated and standard tools for data collection, we acknowledge some limitations as well. First, the cross-sectional nature of our study design is unable to establish temporality or identify mechanisms by which the gut microbiome may causally influence the observed associations. In that regard, we expect that prospective data from the METS cohort study will provide the basis to assess the longitudinal association between gut microbiota composition, metabolites, and obesity, and we have an ongoing study exploring the potential correlations longitudinally. The use of 16S rRNA sequencing in our analysis for inferences on microbial functional ecology inherently has its limitations for drawing conclusions on species and strain level functionality due to its low resolution. Nevertheless, our results provide insight into the relationship between obesity, gut microbiota, and metabolic pathways in individuals of African origin across different geographies, stimulating further examination of large-scale studies using multi-omic approaches with deeper taxonomic and functional resolution and animal transplantation studies to investigate potentially novel microbial strains and to explore the clinical relevance of the observed metabolic differences.

Conclusion

Our study analyzed the relationship between gut microbiota composition, SCFA concentrations, and obesity in a cohort of African origin from different countries. Ghanaian participants had the most diverse microbiota, and the American cohort had the least. Obese individuals had different gut microbiota composition and function compared to non-obese individuals. Non-obese participants had more SCFA-producing microbes and higher total SCFA concentrations in feces. The predictive accuracy of the microbiota for obesity was greatest in low-income countries, suggesting that lifestyle traits in high-income countries may increase obesity risk even for lean individuals. Alterations in the gut microbiota and associated metabolic functions could guide the development of microbiome-based solutions to treat obesity. Further studies using multi-omic approaches are needed to confirm the identified taxonomic and metabolic signatures.

Study Cohort.

Since 2010, METS, and the currently funded METS-Microbiome study has longitudinally followed an international cohort of African origin adults spanning the epidemiologic transition from Ghana, South Africa, Jamaica, Seychelles, and US. METS utilizes the framework of the epidemiologic transition to investigate differences in health outcomes based on country of origin. The epidemiologic transition is defined using the United Nations Human Development Index (HDI) as an approximation of the epidemiologic transition. Ghana represents a lower-middle income country, South Africa represents a middle-income country, Jamaica and Seychelles represent high income countries and the US represents a very high-income country. This framework has allowed us to investigate aspects of increased Westernization throughout the world (ex. increased consumption of ultra-processed foods) are related to increased prevalence of obesity, diabetes and cardiometabolic diseases. Our data from the original METS cohort demonstrate that the epidemiologic transition has altered habitual diets in the international METS sites, and that reduced fiber intake is associated with higher metabolic risk, inflammation, and obesity across the epidemiologic transition. Originally, 2,506 African origin adults (25–45 yrs), were enrolled in METS between January 2010 and December 2011 and followed on a yearly basis. In 2018, METS participants were recontacted and invited to participate in METS-Microbiome. Participants were excluded from participating in the original METS study if they self-reported an infectious disease, including HIV-positive individuals, pregnancy, breast-feeding or any condition which prevented the individual from participating in normal physical activities. METS-Microbiome was approved by the Institutional Review Board of Loyola University Chicago, IL, US; the Committee on Human Research Publication and Ethics of Kwame Nkrumah University of Science and Technology, Kumasi, Ghana; the Research Ethics Committee of the University of Cape Town, South Africa; the Board for Ethics and Clinical Research of the University of Lausanne, Switzerland; and the Ethics Committee of the University of the West Indies, Kingston, Jamaica. All study procedures were explained to participants in their native languages, and participants provided written informed consent after being given the opportunity to ask any questions.

Participant anthropometry, sociodemographic and biochemical measurements.

Participants completed the research visits at the established METS research clinics located in the respective communities. Briefly, they presented themselves at the site-specific research clinic early in the morning, following an overnight fast. The weight of the participant was measured without shoes and dressed in light clothing to the nearest 0.1 kg using a standard digital scale (Seca, SC, USA). Height was measured using a stadiometer without shoes and head held in the Frankfort plane to the nearest 0.1 cm. Waist circumference was measured to the nearest 0.1 cm at the umbilicus, while hip circumference was measured to the nearest 0.1 cm at the point of maximum extension of the buttocks. Adiposity (% body fat) was assessed using BIA (Quantum, RJL Systems, Clinton Township, MI), and study specific equations. Blood pressure was measured using the standard METS protocol using the Omron Automatic Digital Blood Pressure Monitor (model HEM-747Ic, Omron Healthcare, Bannockburn, IL, USA), with the antecubital fossa at heart level. Participants were asked to provide a fecal sample using a standard collection kit (EasySampler stool collection kit, Alpco, NH). Fecal samples were placed within a −80° freezer immediately upon receipt at all the sites. Participants were requested to fast from 8 pm in the evening prior to the clinic examination, during which fasting capillary glucose concentrations were determined using finger stick (Accu-check Aviva, Roche).

Fecal Short Chain Fatty Acid quantification.

As in our previous studies, fecal SCFAs were measured using LC-MC/MS at the University of Illinois-Chicago Mass Spectrometry Core using previously published methods. The LC-MC/MS analysis was completed on an AB Sciex Qtrap 5500 coupled to Agilent UPLC/HPLC system. All samples were analyzed by Agilent poroshell 120 EC-C18 Column, 100Å, 2.7 μm,2.1 mm×100 mm coupled to an Agilent UPLC system, which was operated at a flow rate of 400 μl/min. A gradient of buffer A (H20, 0.1% Formic acid) and buffer B (Acetonitrile, 0.1% Formic acid) were applied as: 0 min, 30% of buffer B; increase buffer B to 100% in 4 min; maintain B at 100% for 5 min. The column was then equilibrated for 3 min at 30% B between the injections with the MS detection is in negative mode. The MRM transitions of all targeted compounds include the precursor ions and the signature production ion. Unit resolution is used for both analyzers Q1 and Q3. The MS parameters such as declustering potential, collision energy and collision cell exit potential are optimized in order to achieve the optimal sensitivity. SCFAs are presented as individual SCFAs (μg/g), including: butyric acid, propionic acid, acetic acid and valeric acid, as well as total SCFAs (sum of 4).

METS data showed Ghanaians consumed the greatest amount of both soluble and insoluble fiber and had the lowest percentage energy from fat (42.5% of the Ghanaian cohort, dietary fiber intake: 24.9 g ±9.7g/day). The US has the highest proportion of energy from fat and the lowest fiber intake of the five sites (3.2% of the US cohort, dietary fiber intake: 14.2 g ± 7.1 g/day).

DNA extraction, Amplicon Sequencing.

Fecal samples were shipped on dry ice to the microbiome core sequencing facility, University of California, San Diego for 16S rRNA gene processing. Fecal samples were randomly sorted, transferred to 96-well extraction plates and DNA was extracted using MagAttract Power Microbiome kit. Blank controls and mock controls (ZymoBiomics) were included per extraction plate, which were carried through all downstream processing steps. Extracted DNA was used for amplification of the V4 region of the 16S rRNA gene with 515F-806R region-specific primers according to the Earth Microbiome Project. Purified amplicon libraries were sequenced on the Illumina NovaSeq platform to produce 150 bp forward and reverse reads through the IGM Genomics Center, University of California San Diego. Full DNA extraction, amplification, quantification, and sequencing protocols and standards are available at http://www.earthmicrobiome.org/protocols-and-standards;.

Bioinformatic analysis.

The generated raw sequence data were uploaded and processed in Qiita (Qiita ID 13512) an open-source, web-enabled microbiome analysis platform. Sequences were demultiplexed, quality filtered, trimmed, erroneous sequences were removed, and amplicon sequence variants (ASVs) were defined using Deblur. The deblur ASV table was exported to Qiime2 and representative sequences of the ASVs were inserted into the Greengenes 13.8 99% identity tree with SATé-enabled phylogenetic placement (SEPP) using q2-fragment-insertion to generate an insertion tree for diversity computation. Additionally, the deblur ASV table was assigned taxonomic classification using the Qiime2 feature-classifier, with Naive Bayes classifiers trained on the SILVA database (version 138;). A total of 463,258,036 reads, 154,952 ASVs and 1902 samples were obtained from the deblur table. The resulting ASV count table, taxonomy data, insertion tree, and sample metadata were exported and merged into a phyloseq object in R (R Foundation for Statistical Computing, Vienna, Austria) for downstream analysis. Features with less than ten reads in the entire dataset and samples with fewer than 6,000 reads were removed from the phyloseq object. In addition, mitochondrial and chloroplast-derived sequences, non-bacterial sequences, as well as ASVs that were unassigned at phylum level were filtered prior to analyses. There were 433,364,873 reads and 13254 ASVs in the remaining 1873 fecal samples in the phyloseq object. The remaining samples after filtering were rarefied to a depth of 6,000 reads to avoid sequencing bias, before generating alpha diversity measures, leaving 9917 ASVs across 1873 samples.

Diversity and differential proportional analyses:

Alpha diversity measures based on Observed Amplicon Sequence Variants (ASVs), Faith’s Phylogenetic Diversity, and Shannon Index were conducted on rarified samples using phyloseq and picante libraries. Beta diversity was determined using both weighted and unweighted UniFrac distance matrices, generated in phyloseq. The Bacteroides Prevotella ratio was calculated by dividing the abundance of the genera Bacteroides by Prevotella. Participants were classified into Bacteroides enterotype (B-type) if the ratio was greater than 1, otherwise Prevotella enterotype (P-type). For differential abundance analysis, samples were processed to remove exceptionally rare taxa. First, the non-rarefied reads were filtered to remove samples with < 10,000 reads. Next, ASVs with fewer than 50 reads in total across all samples and/or were present in less than 2% of samples were excluded. This retained 2061 ASVs across 1694 samples. The retained ASVs were binned at genus level, and subsequently used in the analysis of compositions of microbiomes with bias correction (ANCOMBC; to determine specific taxa differentially abundant across sites or obese phenotype. ANCOM-BC is a statistical approach that accounts for sampling fraction, normalizes the read counts by a process identical to log-ratio transformations while controlling for false discovery rates and increasing power. Site, age, sex, BMI were added as covariates in the ANCOM-BC formula to reduce the effect of confounders.

Random forest classifier:

Random Forest supervised learning models implemented in Qiime2 were used to estimate the predictive power of microbial community profiles for site and obese phenotype. The classifications were done with 500 trees based on 10-fold cross-validation using the QIIME “sample-classifier classify-samples” plugin. A randomly drawn 80% of samples were used for model training, whereas the remaining 20% were used for validation. Further, the 30 most important ASVs for differentiating between site or obese phenotype were predicted and annotated.

Predicted metabolic gene pathway analysis:

The functional potential of microbial communities was inferred using the Phylogenetic Investigation of Communities by Reconstruction of Unobserved States 2 (PICRUSt2) v2.5.1 with the ASV table processed to remove exceptionally rare taxa and the representative sequences as input files. The metabolic pathway from the PICRUSt2 pipeline was annotated using the MetaCyc database. The predicted MetaCyc abundances (unstratified pathway abundances) were analyzed with ANCOM-BC to determine differentially abundant pathway associations across sites and obese status. Site, age, sex, BMI were added as covariates in the ANCOM-BC formula to reduce the effect of confounders.

Statistical Analysis:

All statistical analyses and graphs were done with R software. Kruskal-Wallis test and Permutational Analysis of Variance (PERMANOVA) test with 999 permutations using the Adonis function in the vegan package were performed to compare alpha and beta diversity measures respectively with multiple groups comparison correction. PERMANOVA models were adjusted for BMI, age, sex for country whereas age, sex and country were accounted for in obese groups. Variables that showed significant differences in the PERMANOVA analyses, PERMDISP test was performed to assess differences in dispersion or centroids. For differential abundance analysis, the false-discovery rate (FDR) method incorporated in the ANCOM-BC library was used to correct p-values for multiple testing. A cut-off of Padj < 0.05 was used to assess significance. Spearman correlations were performed between concentrations of short chain fatty acids, Shannon diversity or concentrations of short chain fatty acids and differentially abundant taxa that were identified either among study sites or in obese and non-obese individuals. The resulting p-values were adjusted for multiple testing using the false-discovery rate (FDR). P value < 0.05 was considered statistically significant. A mixed model was built using lme4 package to assess whether total SCFAs could be predicted by Shannon diversity, obesity, and country, setting obesity and Shannon diversity as fixed effects and random intercept by country.

Data availability:

All 16S rRNA gene sequence data are publicly available via the QIITA platform (https://qiita.ucsd.edu) under the study identifier (ID=13512) and will soon be deposited on the European Bioinformatics Institute (EBI) site. The SILVA 16 S rRNA database used for alignment is available at https://data.qiime2.org/2022.2/common/silva-138-99-515-806-nb-classifier.qza. The data and analyses generated in this study are available within the paper, Supplementary Information and Source data files provided with this paper.

References 129

  1. 1.

    Abdelaal Mahmoud, le Roux Carel W., and Docherty Neil G.. 2017. “Morbidity and Mortality Associated with Obesity.” Annals of Translational Medicine 5 (7): 161.

    Not in our library10.21037/atm.2017.03.107

  2. 2.

    Agyemang Charles, Boatemaa Sandra, Frempong Grace Agyemang, and de-Graft Aikins Ama. 2016. “Obesity in Sub-Saharan Africa.” In Metabolic Syndrome: A Comprehensive Textbook,edited by Ahima Rexford S, 41–53. Cham: Springer International Publishing.

    Not in our library

  3. 3.

    Ajala O., Mold F., Boughton C., Cooke D., and Whyte M.. 2017. “Childhood Predictors of Cardiovascular Disease in Adulthood. A Systematic Review and Meta-Analysis.” Obesity Reviews: An Official Journal of the International Association for the Study of Obesity 18 (9): 1061–70.

    Not in our library10.1111/obr.12561

  4. 4.
  5. 5.

    Arumugam Manimozhiyan, Raes Jeroen, Pelletier Eric, Denis Le Paslier Takuji Yamada, Mende Daniel R., Fernandes Gabriel R., 2011. “Enterotypes of the Human Gut Microbiome.” Nature 473 (7346): 174–80.

    Not in our library10.1038/nature09944

  6. 6.

    Asnicar Francesco, Berry Sarah E., Valdes Ana M., Nguyen Long H., Piccinno Gianmarco, Drew David A., Leeming Emily, 2021. “Microbiome Connections with Host Metabolism and Habitual Diet from 1,098 Deeply Phenotyped Individuals.” Nature Medicine 27 (2): 321–32.

    Not in our library10.1038/s41591-020-01183-8

  7. 7.

    Bäckhed Fredrik, Manchester Jill K., Semenkovich Clay F., and Gordon Jeffrey I.. 2007. “Mechanisms Underlying the Resistance to Diet-Induced Obesity in Germ-Free Mice.” Proceedings of the National Academy of Sciences of the United States of America 104 (3): 979–84.

    Not in our library10.1073/pnas.0605374104

  8. 8.

    Barengolts Elena, Green Stefan J., Chlipala George E., Layden Brian T., Eisenberg Yuval, Priyadarshini Medha, and Dugas Lara R.. 2019. “Predictors of Obesity among Gut Microbiota Biomarkers in African American Men with and without Diabetes.” Microorganisms 7 (9)..

    Not in our library10.3390/microorganisms7090320

  9. 9.

    Barone Monica, Garelli Silvia, Rampelli Simone, Agostini Alessandro, Matysik Silke, Federica D’Amico Sabrina Krautbauer, 2022. “Multi-Omics Gut Microbiome Signatures in Obese Women: Role of Diet and Uncontrolled Eating Behavior.” BMC Medicine 20 (1): 500.

    Not in our library10.1186/s12916-022-02689-3

  10. 10.
  11. 11.
  12. 12.

    Bolyen Evan, Jai Ram Rideout Matthew R. Dillon, Bokulich Nicholas A., Abnet Christian C., Al-Ghalith Gabriel A., Alexander Harriet, 2019. “Reproducible, Interactive, Scalable and Extensible Microbiome Data Science Using QIIME 2.” Nature Biotechnology 37 (8): 852–57.

    Not in our library10.1038/s41587-019-0209-9

  13. 13.

    Bonomo Raiza R., Cook Tyler M., Gavini Chaitanya K., White Chelsea R., Jones Jacob R., Bovo Elisa, Zima Aleksey V., 2020. “Fecal Transplantation and Butyrate Improve Neuropathic Pain, Modify Immune Cell Profile, and Gene Expression in the PNS of Obese Mice.” Proceedings of the National Academy of Sciences of the United States of America 117 (42): 26482–93.

    Not in our library10.1073/pnas.2006065117

  14. 14.
  15. 15.

    Canfora Emanuel E., Jocken Johan W., and Blaak Ellen E.. 2015. “Short-Chain Fatty Acids in Control of Body Weight and Insulin Sensitivity.” Nature Reviews. Endocrinology 11 (10): 577–91.

    Not in our library10.1038/nrendo.2015.128

  16. 16.

    Cani Patrice D., Amar Jacques, Miguel Angel Iglesias Marjorie Poggi, Knauf Claude, DelphineBastelica Audrey M. Neyrinck, 2007. “Metabolic Endotoxemia Initiates Obesity and Insulin Resistance.” Diabetes 56 (7): 1761–72.

    Not in our library10.2337/db06-1491

  17. 17.

    Cani Patrice D., Bibiloni Rodrigo, Knauf Claude, Waget Aurélie, Neyrinck Audrey M., Delzenne Nathalie M., and Burcelin Rémy. 2008. “Changes in Gut Microbiota Control Metabolic Endotoxemia-Induced Inflammation in High-Fat Diet-Induced Obesity and Diabetes in Mice.” Diabetes 57 (6): 1470–81.

    Not in our library10.2337/db07-1403

  18. 18.

    Cani Patrice D., and Delzenne Nathalie M.. 2009. “Interplay between Obesity and Associated Metabolic Disorders: New Insights into the Gut Microbiota.” Current Opinion in Pharmacology 9 (6): 737–43.

    Not in our library10.1016/j.coph.2009.06.016

  19. 19.
  20. 20.
  21. 21.
  22. 22.
  23. 23.

    Clemente Jose C., Pehrsson Erica C., Blaser Martin J., Sandhu Kuldip, Gao Zhan, Wang Bin, Magris Magda, 2015. “The Microbiome of Uncontacted Amerindians.” Science Advances 1 (3)..

    Not in our library10.1126/sciadv.1500183

  24. 24.
  25. 25.

    Costello Elizabeth K., Stagaman Keaton, Dethlefsen Les, Bohannan Brendan J. M., and Relman David A.. 2012. “The Application of Ecological Theory toward an Understanding of the Human Microbiome.” Science 336 (6086): 1255–62.

    Not in our library10.1126/science.1224203

  26. 26.

    Cuesta-Zuluaga Jacobo de la, Corrales-Agudelo Vanessa, Velásquez-Mejía Eliana P., Carmona Jenny A., Abad José M., and Escobar Juan S.. 2018. “Gut Microbiota Is Associated with Obesity and Cardiometabolic Disease in a Population in the Midst of Westernization.” Scientific Reports 8 (1): 11356.

    Not in our library10.1038/s41598-018-29687-x

  27. 27.
  28. 28.

    Dahl Wendy J., and Stewart Maria L.. 2015. “Position of the Academy of Nutrition and Dietetics: Health Implications of Dietary Fiber.” Journal of the Academy of Nutrition and Dietetics 115 (11): 1861–70.

    Not in our library10.1016/j.jand.2015.09.003

  29. 29.

    Dalile Boushra, Lukas Van Oudenhove Bram Vervliet, and Verbeke Kristin. 2019. “The Role of Short-Chain Fatty Acids in Microbiota-Gut-Brain Communication.” Nature Reviews. Gastroenterology & Hepatology 16 (8): 461–78.

    Not in our library10.1038/s41575-019-0157-3

  30. 30.

    Filippis De, Francesca Nicoletta Pellegrini, Vannini Lucia, Jeffery Ian B., Antonietta La Storia Luca Laghi, Serrazanetti Diana I., 2016. “High-Level Adherence to a Mediterranean Diet Beneficially Impacts the Gut Microbiota and Associated Metabolome.” Gut 65 (11): 1812–21.

    Not in our library10.1136/gutjnl-2015-309957

  31. 31.

    Filippo De, Carlotta Duccio Cavalieri, Monica Di Paola Matteo Ramazzotti, Jean Baptiste Poullet Sebastien Massart, Collini Silvia, Pieraccini Giuseppe, and Lionetti Paolo. 2010. “Impact of Diet in Shaping Gut Microbiota Revealed by a Comparative Study in Children from Europe and Rural Africa.” Proceedings of the National Academy of Sciences of the United States of America 107 (33): 14691–96.

    Not in our library10.1073/pnas.1005963107

  32. 32.
  33. 33.

    DiBaise John K., Zhang Husen, Crowell Michael D., Krajmalnik-Brown Rosa, Decker G. Anton, and Rittmann Bruce E.. 2008. “Gut Microbiota and Its Possible Relationship with Obesity.” Mayo Clinic Proceedings. Mayo Clinic 83 (4): 460–69.

    Not in our library10.4065/83.4.460

  34. 34.

    Douglas Gavin M., Maffei Vincent J., Zaneveld Jesse R., Yurgel Svetlana N., Brown James R., Taylor Christopher M., Huttenhower Curtis, and Langille Morgan G. I.. 2020. “PICRUSt2 for Prediction of Metagenome Functions.” Nature Biotechnology 38 (6): 685–88.

    Not in our library10.1038/s41587-020-0548-6

  35. 35.

    Dugas Lara R., Beatriz Peñalver Bernabé Medha Priyadarshini, Fei Na, Seo Jin Park Laquita Brown, Plange-Rhule Jacob, 2018. “Decreased Microbial Co-Occurrence Network Stability and SCFA Receptor Level Correlates with Obesity in African-Origin Women.” Scientific Reports 8 (1): 17135.

    Not in our library10.1038/s41598-018-35230-9

  36. 36.

    Dugas Lara R., Lie Louise, Jacob Plange-Rhule Kweku Bedu-Addo, Bovet Pascal, Lambert Estelle V., Forrester Terrence E., Luke Amy, Gilbert Jack A., and Layden Brian T.. 2018. “Gut Microbiota, Short Chain Fatty Acids, and Obesity across the Epidemiologic Transition: The METS-Microbiome Study Protocol.” BMC Public Health 18 (1): 978.

    Not in our library10.1186/s12889-018-5879-6

  37. 37.

    Ecklu-Mensah Gertrude, Gilbert Jack, and Devkota Suzanne. 2022. “Dietary Selection Pressures and Their Impact on the Gut Microbiome.” Cellular and Molecular Gastroenterology and Hepatology 13(1): 7–18.

    Not in our library10.1016/j.jcmgh.2021.07.009

  38. 38.

    Esposito Katherine, Kastorini Christina-Maria, Panagiotakos Demosthenes B., and Giugliano Dario. 2011. “Mediterranean Diet and Weight Loss: Meta-Analysis of Randomized Controlled Trials.” Metabolic Syndrome and Related Disorders 9 (1): 1–12.

    Not in our library10.1089/met.2010.0031

  39. 39.

    Falony Gwen, Joossens Marie, Sara Vieira-Silva Jun Wang, Darzi Youssef, Faust Karoline, Kurilshikov Alexander, 2016. “Population-Level Analysis of Gut Microbiome Variation.” Science 352 (6285): 560–64.

    Not in our library10.1126/science.aad3503

  40. 40.

    Fei Na, Beatriz Peñalver Bernabé Louise Lie, Baghdan Danny, Kweku Bedu-Addo Jacob Plange-Rhule, Forrester Terrence E., 2019. “The Human Microbiota Is Associated with Cardiometabolic Risk across the Epidemiologic Transition.” PloS One 14 (7): e0215262.

    Not in our library10.1371/journal.pone.0215262

All 129 references

Cited by papers we hold 1

Reads

Read by people on this page

None yet.

Checked or read by AI through naulon

None yet.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.

Are you an author?

Is this your paper?

Claim it to add your note and be paid when agents cite it. Free.